Design Therapeutics reports Q3 net loss of $15.8M, extends cash runway to 5 years, appoints Pratik Shah as CEO

Design Therapeutics, Inc.

2023-Q3 EPS reported -$0.98

Net loss of $15.8M for Q3 2023; R&D expenses $13.3M, G&A expenses $5.6M.
Cash and securities of $290.9M as of Sep 30, 2023, expected to fund operations through at least 2028.
Strategic realignment initiated to prioritize long-term growth, focus capital, and implement cost savings.
Pratik Shah appointed as Chief Executive Officer, leading company turnaround and portfolio review.
Comprehensive corporate and pipeline update planned for early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Design Therapeutics, Inc. reported third quarter 2023 results: net income Net loss was $15.8 million for the quarter ended September 30, 2023.. Guidance reaffirmed.

Period: third quarter 2023
Net income: Net loss was $15.8 million for the quarter ended September 30, 2023.
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results.

View on SEC.gov

Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.